股票 
板块 
用户 
资讯 Swipe Left for English News→
博腾股份将参加2026年9月29日至10月1日在西班牙Bilbao展览中心（Bilbao Exhibition Centre）2号展馆举办的BIOSPAIN 2026。作为欧洲规模最大的生物技术盛会之一，BIOSPAIN由西班牙生物产业协会（AseBio）主办，本届大会以“Bioinnovation that clicks”为主题，博腾股份将在#174号展位亮相，与全球生物医药企业、行业专家及合作伙伴共探前沿科技与未来合作机遇。
BIOSPAIN是全球范围内一对一会议数量和参展企业规模领先的国际性行业展会。2025年巴塞罗那展会创下历史纪录：来自35个国家的2,400余名参会者、1,065家企业、140家投资机构参与，促成超过4,500场一对一会议。今年，BIOSPAIN首次转为年度举办，移师西班牙最重要的生物技术产业枢纽之一——Bilbao。
在#174号展位，博腾股份将全面展示其从临床前研究到药品上市全生命周期的端到端定制研发与生产服务，涵盖小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物的原料药到制剂全流程。依托FDA、EMA、WHO、PMDA及NMPA等全球权威监管机构的成功审计与认证，博腾始终坚持以创新、高效和可持续发展为核心，致力于为客户提供创新可靠的全球化CDMO解决方案，让好药更早惠及大众。
博腾股份诚邀全球生物医药企业、专家学者及投资者在BIOSPAIN 2026期间莅临#174号展位，面对面交流探讨，共同推动生物医药行业的创新与融合。
预约现场会议：
点击“”访问博腾官网进行预约
发送邮件至：business@portonpharma.com
博腾专业团队将及时为您安排会议，并提供定制化解决方案。
END
博腾股份成立于2005年，为全球药企、生物科技公司及科研机构等提供从临床前研究到药品上市全生命周期的端到端CDMO服务，涵盖小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物的原料药到制剂全流程。截至2025年末，公司拥有全球员工4300余人，累计服务客户1400余家，成功交付项目超5000个。我们始终坚持以客户为中心，致力于提供创新可靠的全球化CDMO解决方案，让好药更早惠及大众。
Porton Pharma Solutions Ltd. announced its participation in BIOSPAIN 2026, one of Europe's largest biotechnology events, taking place from September 29 to October 1, 2026 at Bilbao Exhibition Centre (BEC) in Bilbao, Spain. Organized by the Spanish Bioindustry Association (AseBio), this year's edition is held under the theme “Bioinnovation that clicks”. Porton will be exhibiting at Booth #174, engaging with global biopharmaceutical companies, industry experts, and partners to explore cutting-edge technologies and future collaboration opportunities.
BIOSPAIN is one of the largest biotech events organized by a national bioindustry association in Europe and one of the world's largest by the number of one-to-one meetings and participating companies. The 2025 edition in Barcelona set new records, welcoming more than 2,400 attendees from 35 countries, 1,065 companies, and 140 investors, facilitating over 4,500 one-to-one meetings. This year, BIOSPAIN becomes an annual event for the first time and moves to Bilbao, one of Spain's leading biotechnology clusters and most avant-garde cities.
At Booth #174, Porton will proudly showcase its end-to-end, customized R&D and GMP manufacturing services to pharmaceutical and biotech companies, as well as research institutions worldwide, spanning the entire drug lifecycle from pre-clinical development to commercialization. Our capabilities cover both drug substances (APIs) and drug products across multiple modalities, including Small Molecules, TIDES, Biologics and Conjugates (ADCs, AOCs, DACs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products.Backed by stringent quality standards and successful inspections from the FDA, EMA, WHO, PMDA, and NMPA, we are committed to a customer-centric approach, delivering innovative and reliable global CDMO solutions, enabling earlier access to good medicines.
Porton extends a warm invitation to global biopharmaceutical companies, research institutions, and investors to visit Booth #174 at BIOSPAIN 2026 for face-to-face discussions to shape the future of biopharma together.
To schedule an onsite meeting:
Visit the offline meeting section on Porton's official website (click read more)
Email us at: business@portonpharma.com
Our professional team will be glad to arrange a dedicated session and provide tailored solutions for your needs.
END
Founded in 2005, Porton Pharma Solutions provides end-to-end CDMO services from pre-clinical to commercial stages. Our capabilities span Small Molecules, TIDES, Biologics and Conjugates (ADCs, AOCs, DACs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products, from drug substance to drug product. As of 2025, Porton has over 4,300 employees globally, served more than 1,400 customers, and delivered over 5,000 projects. We are committed to a customer-centric approach, delivering innovative and reliable global CDMO solutions, enabling earlier access to good medicines.
评论 (0)